Moleculin reports Q1 2023 cash of $37.3M, R&D expense up to $5.7M; Annamycin trial advances

Moleculin Biotech, Inc.

Cash and equivalents of $37.3M as of March 31, 2023, expected to fund operations into Q3 2024.
R&D expense increased to $5.7M from $4.6M YoY, primarily due to WPD sublicense termination.
G&A expense increased to $2.6M from $2.4M YoY, driven by higher regulatory, legal, and consulting fees.
Phase 1b/2 trial of Annamycin in AML (MB-106) completed first cohort; positive preclinical data presented at AACR 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.96

Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and recent operational highlights.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-013762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.